130 related articles for article (PubMed ID: 19842932)
1. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.
Elens L; Yombi JC; Lison D; Wallemacq P; Vandercam B; Haufroid V
Pharmacogenomics; 2009 Oct; 10(10):1589-97. PubMed ID: 19842932
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children.
Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN
Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
[TBL] [Abstract][Full Text] [Related]
4. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
5. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
[TBL] [Abstract][Full Text] [Related]
6. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
Gupta SK; Rosenkranz SL; Cramer YS; Koletar SL; Szczech LA; Amorosa V; Hall SD
AIDS; 2008 Oct; 22(15):1919-27. PubMed ID: 18784455
[TBL] [Abstract][Full Text] [Related]
8. Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.
Mpeta B; Kampira E; Castel S; Mpye KL; Soko ND; Wiesner L; Smith P; Skelton M; Lacerda M; Dandara C
Pharmacogenomics; 2016 May; 17(7):679-90. PubMed ID: 27142945
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.
Gutiérrez F; Padilla S; Navarro A; Masiá M; Hernández I; Ramos J; Esteban A; Martin-Hidalgo A
J Acquir Immune Defic Syndr; 2003 Aug; 33(5):594-600. PubMed ID: 12902803
[TBL] [Abstract][Full Text] [Related]
10. An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients.
Azoulay S; Nevers MC; Créminon C; Heripret L; Garraffo R; Durant J; Dellamonica P; Grassi J; Guedj R; Duval D
J Immunol Methods; 2004 Dec; 295(1-2):37-48. PubMed ID: 15627609
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.
López Aspiroz E; Cabrera Figueroa SE; Porras Hurtado GL; Cruz Guerrero R; Domínguez-Gil Hurlé A; Carracedo A;
Curr Drug Metab; 2013 Sep; 14(7):729-37. PubMed ID: 24001122
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Colombo S; Buclin T; Franc C; Guignard N; Khonkarly M; Tarr PE; Rochat B; Biollaz J; Telenti A; Decosterd LA; Cavassini M
Antivir Ther; 2006; 11(1):53-62. PubMed ID: 16518960
[TBL] [Abstract][Full Text] [Related]
13. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Crommentuyn KM; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Antivir Ther; 2004 Oct; 9(5):779-85. PubMed ID: 15535416
[TBL] [Abstract][Full Text] [Related]
14. Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.
Barragan P; Podzamczer D
Expert Opin Pharmacother; 2008 Sep; 9(13):2363-75. PubMed ID: 18710360
[TBL] [Abstract][Full Text] [Related]
15. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
[TBL] [Abstract][Full Text] [Related]
16. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
17. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
18. Lopinavir/ritonavir (ABT-378/r).
Qazi NA; Morlese JF; Pozniak AL
Expert Opin Pharmacother; 2002 Mar; 3(3):315-27. PubMed ID: 11866671
[TBL] [Abstract][Full Text] [Related]
19. Influence of SLCO1B1 polymorphisms on lopinavir C
Dragović G; Dimitrijević B; Kušić J; Soldatović I; Jevtović D; Olagunju A; Owen A
Br J Clin Pharmacol; 2020 Jul; 86(7):1289-1295. PubMed ID: 32022294
[TBL] [Abstract][Full Text] [Related]
20. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study).
Breilh D; Pellegrin I; Rouzés A; Berthoin K; Xuereb F; Budzinski H; Munck M; Fleury HJ; Saux MC; Pellegrin JL
AIDS; 2004 Jun; 18(9):1305-10. PubMed ID: 15362663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
